Jo Salkeld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jo Salkeld has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Angela M. Minassian
The Jenner Institute, University of Oxford, UK
10 shared publications - Simon J. Draper
University of Oxford
10 shared publications Jee-Sun Cho
Department of Paediatrics, Department of Biochemistry and Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, United Kingdom
8 shared publicationsAlison M. Lawrie
The National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom
6 shared publicationsCarolyn M. Nielsen
Department of Paediatrics, Department of Biochemistry and Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, United Kingdom
6 shared publicationsJordan R. Barrett
Department of Paediatrics, Department of Biochemistry and Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, United Kingdom
6 shared publications
Latest Publications
- Open Access
Establishing a blood-stage controlled human malaria infection model with Plasmodium falciparum in healthy semi-immune Tanzanian adults
Controlled human malaria infection (CHMI) studies are a critical tool for the assessment and down-selection of potential malaria interventions, allowing detailed characterisation and understanding of host-parasite responses to inform both malaria vaccine and antimalarial drug development in humans. Blood-stage CHMI offers a specific means for proof-of-concept testing of blood-stage malaria vaccines, bypassing the pre-erythrocytic stages of malaria infection. Here, we establish a blood-stage CHMI model in an endemic region in a clinical study involving 12 healthy semi-immune male adult participants residing in Bagamoyo district, Tanzania. Participants were enrolled into relatively “low” (n=6) and “high” (n=6) malaria pre-exposure groups as defined by serum anti-schizont IgG levels. Participants were challenged with approximately 1000 erythrocytes infected with a chloroquine-sensitive Plasmodium falciparum 3D7 clone and closely monitored for 28 days at the Ifakara Health Institute clinical trial facility in Bagamoyo. Blood samples were collected for safety and immunology assessments, with venous blood samples for P. falciparum quantitative polymerase chain reaction (qPCR) taken once on day after challenge (C+1) and twice daily from two to 28 days after challenge (C+2 to C+28). Participants were treated once pre-defined diagnostic criteria were met or at day 28 (if criteria not met). The challenge inoculum was found to be safe with the severity grading of adverse events (AEs) in keeping with previous challenge studies. Overall, fewer AEs were reported as compared to malaria-naïve UK adults previously challenged with the same inoculum dose, despite a 50-fold higher treatment threshold being used in Tanzanian adults. Nine of 11 participants developed parasitaemia detectable by qPCR and one participant was retrospectively excluded from parasitaemia endpoint analysis due to non-3D7 type infection. The two participants who remained qPCR negative were both in the “high” pre-exposure group. Higher anti-schizont baseline serology status was associated with later median time to parasitaemia detection and time to pre-defined treatment criteria. These data demonstrate that blood-stage CHMI is safe and feasible in semi-immune adults in a malaria-endemic setting.
Open AccessEstablishing a blood-stage controlled human malaria infection model with Plasmodium falciparum in healthy semi-immune Tanzanian adults
Controlled human malaria infection (CHMI) studies are a critical tool for the assessment and down-selection of potential malaria interventions, allowing detailed characterisation and understanding of host-parasite responses to inform both malaria vaccine and antimalarial drug development in humans. Blood-stage CHMI offers a specific means for proof-of-concept testing of blood-stage malaria vaccines, bypassing the pre-erythrocytic stages of malaria infection. Here, we establish a blood-stage CHMI model in an endemic region in a clinical study involving 12 healthy semi-immune male adult participants residing in Bagamoyo district, Tanzania. Participants were enrolled into relatively “low” (n=6) and “high” (n=6) malaria pre-exposure groups as defined by serum anti-schizont IgG levels. Participants were challenged with approximately 1000 erythrocytes infected with a chloroquine-sensitive Plasmodium falciparum 3D7 clone and closely monitored for 28 days at the Ifakara Health Institute clinical trial facility in Bagamoyo. Blood samples were collected for safety and immunology assessments, with venous blood samples for P. falciparum quantitative polymerase chain reaction (qPCR) taken once on day after challenge (C+1) and twice daily from two to 28 days after challenge (C+2 to C+28). Participants were treated once pre-defined diagnostic criteria were met or at day 28 (if criteria not met). The challenge inoculum was found to be safe with the severity grading of adverse events (AEs) in keeping with previous challenge studies. Overall, fewer AEs were reported as compared to malaria-naïve UK adults previously challenged with the same inoculum dose, despite a 50-fold higher treatment threshold being used in Tanzanian adults. Nine of 11 participants developed parasitaemia detectable by qPCR and one participant was retrospectively excluded from parasitaemia endpoint analysis due to non-3D7 type infection. The two participants who remained qPCR negative were both in the “high” pre-exposure group. Higher anti-schizont baseline serology status was associated with later median time to parasitaemia detection and time to pre-defined treatment criteria. These data demonstrate that blood-stage CHMI is safe and feasible in semi-immune adults in a malaria-endemic setting.
- Open Access
- 29 December 2025
- Published by F1000 Research Ltd in VeriXiv
Structural basis for synergistic antibody protection against the essential malaria invasion complex protein RIPR
- 29 December 2025
- Published by F1000 Research Ltd in VeriXiv
Open AccessStructural basis for synergistic antibody protection against the essential malaria invasion complex protein RIPR
- Open Access
Structural basis for synergistic antibody protection against the essential malaria invasion complex protein RIPR
Plasmodium falciparum RH5-interacting protein (RIPR) is the central component of the essential pentameric PTRAMP-CSS-RIPR-CyRPA-RH5 (PCRCR)-complex; a leading target of next-generation blood-stage malaria vaccines. However, the mechanisms whereby anti-RIPR antibodies inhibit malaria parasite invasion of erythrocytes are poorly understood. Here, we characterise 83 human IgG mAbs from RIPR-vaccinated Kymouse platform mice. Single mAbs have minimal neutralising activity, however, high-level synergistic growth inhibition is observed when using pools of mAbs targeting the flexible RIPR-Tail region. Structural characterisation and molecular dynamics simulations of the RIPR-Tail show that mAbs targeting EGF-like domains 6-8 (RIPR EGF (6-8) ), but not EGF-like domains 9-10 or the C-terminal domain (RIPR EGF (9-10)-CTD ), synergise to constrain the RIPR-Tail conformation. The same antibodies also dissociate PTRAMP-CSS from RIPR, thereby enabling anti-RIPR EGF (9-10)-CTD mAbs or anti-CSS single-domain antibodies to bind and potentiate the anti-RIPR EGF (6-8) IgG. Addition of these mAbs to IgG from humans immunised with the R78C (RIPR EGF (7-8) -CyRPA) candidate vaccine enhances malaria growth inhibition. These data provide a framework to guide design of next-generation blood-stage malaria vaccines.
Open AccessStructural basis for synergistic antibody protection against the essential malaria invasion complex protein RIPR
Plasmodium falciparum RH5-interacting protein (RIPR) is the central component of the essential pentameric PTRAMP-CSS-RIPR-CyRPA-RH5 (PCRCR)-complex; a leading target of next-generation blood-stage malaria vaccines. However, the mechanisms whereby anti-RIPR antibodies inhibit malaria parasite invasion of erythrocytes are poorly understood. Here, we characterise 83 human IgG mAbs from RIPR-vaccinated Kymouse platform mice. Single mAbs have minimal neutralising activity, however, high-level synergistic growth inhibition is observed when using pools of mAbs targeting the flexible RIPR-Tail region. Structural characterisation and molecular dynamics simulations of the RIPR-Tail show that mAbs targeting EGF-like domains 6-8 (RIPR EGF (6-8) ), but not EGF-like domains 9-10 or the C-terminal domain (RIPR EGF (9-10)-CTD ), synergise to constrain the RIPR-Tail conformation. The same antibodies also dissociate PTRAMP-CSS from RIPR, thereby enabling anti-RIPR EGF (9-10)-CTD mAbs or anti-CSS single-domain antibodies to bind and potentiate the anti-RIPR EGF (6-8) IgG. Addition of these mAbs to IgG from humans immunised with the R78C (RIPR EGF (7-8) -CyRPA) candidate vaccine enhances malaria growth inhibition. These data provide a framework to guide design of next-generation blood-stage malaria vaccines.
- Open Access
- 25 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection
Clinical immunity to malaria can lead to asymptomatic infection, but the underlying mechanisms remain unclear. To examine the development of clinical immunity, we conducted a multi-cohort, repeat controlled human malaria infection (CHMI) study with Plasmodium vivax, and a heterologous rechallenge with P. falciparum (ClinicalTrials.gov NCT03797989). Malaria-naïve adults underwent CHMI up to three times, by administration of red blood cells infected with P. vivax PvW1 clone or P. falciparum 3D7 clone. Nineteen participants underwent primary CHMI with P. vivax, 12 returned for secondary homologous CHMI and 2 for tertiary homologous CHMI. Six participants who had completed P. vivax CHMI then underwent heterologous rechallenge with P. falciparum. We find that clinical immunity to P. vivax develops rapidly after a single CHMI, protecting participants against fever and laboratory abnormalities. This is underpinned by the attenuation of inflammatory cytokines and chemokines, as well as reduced coagulation and endothelium activation. In contrast, there is no evidence of anti-parasite immunity, suggesting that mechanisms of clinical immunity can operate independently of pathogen load to reduce the damage caused by malaria infection. In addition, we show that clinical immunity to P. vivax is parasite species-specific and provides no protection against CHMI with P. falciparum.
- 25 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Open AccessDevelopment of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection
Clinical immunity to malaria can lead to asymptomatic infection, but the underlying mechanisms remain unclear. To examine the development of clinical immunity, we conducted a multi-cohort, repeat controlled human malaria infection (CHMI) study with Plasmodium vivax, and a heterologous rechallenge with P. falciparum (ClinicalTrials.gov NCT03797989). Malaria-naïve adults underwent CHMI up to three times, by administration of red blood cells infected with P. vivax PvW1 clone or P. falciparum 3D7 clone. Nineteen participants underwent primary CHMI with P. vivax, 12 returned for secondary homologous CHMI and 2 for tertiary homologous CHMI. Six participants who had completed P. vivax CHMI then underwent heterologous rechallenge with P. falciparum. We find that clinical immunity to P. vivax develops rapidly after a single CHMI, protecting participants against fever and laboratory abnormalities. This is underpinned by the attenuation of inflammatory cytokines and chemokines, as well as reduced coagulation and endothelium activation. In contrast, there is no evidence of anti-parasite immunity, suggesting that mechanisms of clinical immunity can operate independently of pathogen load to reduce the damage caused by malaria infection. In addition, we show that clinical immunity to P. vivax is parasite species-specific and provides no protection against CHMI with P. falciparum.
- Open Access
An experimental model of clinical immunity for human malaria
Clinical immunity to malaria can reduce fever and lead to asymptomatic infection but the underlying mechanisms remain unclear. To examine the development of clinical immunity, we conducted a multi-cohort, repeat controlled human malaria infection (CHMI) study with Plasmodium vivax , and a heterologous rechallenge with P. falciparum . Malaria-naïve adults underwent P. vivax CHMI up to three times, at an interval of 5 to 20 months, by administration of red blood cells infected with the P. vivax PvW1 clone. In the final cohort of the study, a subset of participants underwent heterologous repeat CHMI with the P. falciparum 3D7 clone. Clinical parameters and the host response to infection were measured up to 3 months after each CHMI. Nineteen participants underwent primary CHMI with P. vivax , 12 returned for secondary homologous CHMI and 2 for tertiary homologous CHMI with the same parasite clone. During rechallenge, parasite growth was not attenuated and there was minimal induction of invasion-blocking antibodies. Nonetheless, clinical symptoms including fever and laboratory abnormalities were less frequent and of lower severity during rechallenge and multi-analyte plasma profiling revealed an attenuated inflammatory response. Six participants who had completed P. vivax CHMI, then underwent heterologous rechallenge with P. falciparum . Previous infection with P. vivax did not protect participants against symptoms, fever or inflammation upon exposure to P. falciparum . Clinical immunity to P. vivax developed rapidly after a single CHMI, protecting participants against fever and laboratory abnormalities associated with malaria and was underpinned by the attenuation of inflammation. In contrast, there was no evidence of anti-parasite immunity, suggesting that mechanisms of clinical immunity can operate independently of pathogen load to reduce the damage caused by malaria. Clinical immunity to P. vivax was parasite species-specific and provided no protection against CHMI with P. falciparum .
Open AccessAn experimental model of clinical immunity for human malaria
Clinical immunity to malaria can reduce fever and lead to asymptomatic infection but the underlying mechanisms remain unclear. To examine the development of clinical immunity, we conducted a multi-cohort, repeat controlled human malaria infection (CHMI) study with Plasmodium vivax , and a heterologous rechallenge with P. falciparum . Malaria-naïve adults underwent P. vivax CHMI up to three times, at an interval of 5 to 20 months, by administration of red blood cells infected with the P. vivax PvW1 clone. In the final cohort of the study, a subset of participants underwent heterologous repeat CHMI with the P. falciparum 3D7 clone. Clinical parameters and the host response to infection were measured up to 3 months after each CHMI. Nineteen participants underwent primary CHMI with P. vivax , 12 returned for secondary homologous CHMI and 2 for tertiary homologous CHMI with the same parasite clone. During rechallenge, parasite growth was not attenuated and there was minimal induction of invasion-blocking antibodies. Nonetheless, clinical symptoms including fever and laboratory abnormalities were less frequent and of lower severity during rechallenge and multi-analyte plasma profiling revealed an attenuated inflammatory response. Six participants who had completed P. vivax CHMI, then underwent heterologous rechallenge with P. falciparum . Previous infection with P. vivax did not protect participants against symptoms, fever or inflammation upon exposure to P. falciparum . Clinical immunity to P. vivax developed rapidly after a single CHMI, protecting participants against fever and laboratory abnormalities associated with malaria and was underpinned by the attenuation of inflammation. In contrast, there was no evidence of anti-parasite immunity, suggesting that mechanisms of clinical immunity can operate independently of pathogen load to reduce the damage caused by malaria. Clinical immunity to P. vivax was parasite species-specific and provided no protection against CHMI with P. falciparum .
- Open Access
- 25 October 2024
- Published by Elsevier in Clinical Medicine
- Vol. 24 (6) , 100258
Malaria: Past, present and future
- 25 October 2024
- Published by Elsevier in Clinical Medicine
- Vol. 24 (6) , 100258
Open AccessMalaria: Past, present and future
- Open Access
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled phase 2b trial in children
Background: Two pre-erythrocytic vaccines (R21/Matrix-M and RTS,S/AS01) are now approved for P. falciparum malaria. However, neither induces blood-stage immunity against parasites that breakthrough from the liver. RH5.1/Matrix-M, a blood-stage P. falciparum malaria vaccine candidate, was highly immunogenic in Tanzanian adults and children. We therefore assessed the safety and efficacy of RH5.1/Matrix-M in Burkinabe children. Methods: In this double-blind, randomised, controlled phase 2b trial, RH5.1/Matrix-M was given to children aged 5-17 months in Nanoro, Burkina Faso – a seasonal malaria transmission setting. Children received either three intramuscular vaccinations with 10 µg RH5.1 protein with 50 µg Matrix-M adjuvant or three doses of rabies control vaccine, Rabivax-S, given either in a delayed third dose (0-1-5-month) regimen (first cohort) or a 0-1-2-month regimen (second cohort). Vaccinations were completed part-way through the malaria season. Children were randomly assigned 2:1 within each cohort to receive RH5.1/Matrix-M or Rabivax-S. Participants were assigned according to a random allocation list generated by an independent statistician using block randomisation with variable block sizes. Participants, their families, and the study teams were masked to group allocation; only pharmacists who prepared the vaccines were unmasked. Vaccine safety, immunogenicity, and efficacy were evaluated. Co-primary objectives assessed were: i) safety and reactogenicity of RH5.1/Matrix-M, and ii) protective efficacy of RH5.1/Matrix-M against clinical malaria from 14 days to 6 months post-third vaccination in the per-protocol population. This trial is registered with ClinicalTrials.gov ( NCT05790889 ). Findings: From 6 th to 13 th April and 3 rd to 7 th July 2023, 412 children aged 5-17 months were screened, and 51 were excluded. A total of 361 children were enrolled in this study. In the first cohort, 119 were assigned to the RH5.1/Matrix-M delayed third dose group, and 62 to the equivalent rabies control group. The second cohort included 120 children in the monthly RH5.1/Matrix-M group and 60 in the equivalent rabies control group. The final vaccination was administered to all groups from 4 th to 21 st September 2023. RH5.1/Matrix-M in both cohorts had a favourable safety profile and was well tolerated. Most adverse events were mild, with the most common being local swelling and fever. No serious adverse events were reported. A Cox regression model was used to analyse the primary endpoint of time to first episode of clinical malaria, according to the primary case definition, within 14 days to 6 months post-third vaccination. Comparing the RH5.1/Matrix-M delayed third dose regimen with the pooled control groups resulted in vaccine efficacy of 55% (95% CI 20-75%; p=0·0071). The same analysis showed a vaccine efficacy of 40% (95% CI -3-65%; p=0·066) when comparing the monthly regimen with the pooled control groups. Participants vaccinated with RH5.1/Matrix-M in both cohorts showed high concentrations of anti-RH5.1 serum IgG antibodies 14 days post-third vaccination, and the purified IgG showed high levels of in vitro growth inhibition activity (GIA) against P. falciparum ; these responses were higher in RH5.1/Matrix-M vaccinees who received the delayed third dose, as opposed to monthly, regimen. Interpretation: RH5.1/Matrix-M appears safe and highly immunogenic in African children and shows promising efficacy against clinical malaria when given in a delayed third dose regimen. This trial remains ongoing to further monitor efficacy over time. Funding: The European and Developing Countries Clinical Trials Partnership; the UK Medical Research Council; the National Institute for Health and Care Research Oxford Biomedical Research Centre; the Division of Intramural Research, National Institute of Allergy and Infectious Diseases; the US Agency for International Development; and the Wellcome Trust.
Open AccessSafety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled phase 2b trial in children
Background: Two pre-erythrocytic vaccines (R21/Matrix-M and RTS,S/AS01) are now approved for P. falciparum malaria. However, neither induces blood-stage immunity against parasites that breakthrough from the liver. RH5.1/Matrix-M, a blood-stage P. falciparum malaria vaccine candidate, was highly immunogenic in Tanzanian adults and children. We therefore assessed the safety and efficacy of RH5.1/Matrix-M in Burkinabe children. Methods: In this double-blind, randomised, controlled phase 2b trial, RH5.1/Matrix-M was given to children aged 5-17 months in Nanoro, Burkina Faso – a seasonal malaria transmission setting. Children received either three intramuscular vaccinations with 10 µg RH5.1 protein with 50 µg Matrix-M adjuvant or three doses of rabies control vaccine, Rabivax-S, given either in a delayed third dose (0-1-5-month) regimen (first cohort) or a 0-1-2-month regimen (second cohort). Vaccinations were completed part-way through the malaria season. Children were randomly assigned 2:1 within each cohort to receive RH5.1/Matrix-M or Rabivax-S. Participants were assigned according to a random allocation list generated by an independent statistician using block randomisation with variable block sizes. Participants, their families, and the study teams were masked to group allocation; only pharmacists who prepared the vaccines were unmasked. Vaccine safety, immunogenicity, and efficacy were evaluated. Co-primary objectives assessed were: i) safety and reactogenicity of RH5.1/Matrix-M, and ii) protective efficacy of RH5.1/Matrix-M against clinical malaria from 14 days to 6 months post-third vaccination in the per-protocol population. This trial is registered with ClinicalTrials.gov ( NCT05790889 ). Findings: From 6 th to 13 th April and 3 rd to 7 th July 2023, 412 children aged 5-17 months were screened, and 51 were excluded. A total of 361 children were enrolled in this study. In the first cohort, 119 were assigned to the RH5.1/Matrix-M delayed third dose group, and 62 to the equivalent rabies control group. The second cohort included 120 children in the monthly RH5.1/Matrix-M group and 60 in the equivalent rabies control group. The final vaccination was administered to all groups from 4 th to 21 st September 2023. RH5.1/Matrix-M in both cohorts had a favourable safety profile and was well tolerated. Most adverse events were mild, with the most common being local swelling and fever. No serious adverse events were reported. A Cox regression model was used to analyse the primary endpoint of time to first episode of clinical malaria, according to the primary case definition, within 14 days to 6 months post-third vaccination. Comparing the RH5.1/Matrix-M delayed third dose regimen with the pooled control groups resulted in vaccine efficacy of 55% (95% CI 20-75%; p=0·0071). The same analysis showed a vaccine efficacy of 40% (95% CI -3-65%; p=0·066) when comparing the monthly regimen with the pooled control groups. Participants vaccinated with RH5.1/Matrix-M in both cohorts showed high concentrations of anti-RH5.1 serum IgG antibodies 14 days post-third vaccination, and the purified IgG showed high levels of in vitro growth inhibition activity (GIA) against P. falciparum ; these responses were higher in RH5.1/Matrix-M vaccinees who received the delayed third dose, as opposed to monthly, regimen. Interpretation: RH5.1/Matrix-M appears safe and highly immunogenic in African children and shows promising efficacy against clinical malaria when given in a delayed third dose regimen. This trial remains ongoing to further monitor efficacy over time. Funding: The European and Developing Countries Clinical Trials Partnership; the UK Medical Research Council; the National Institute for Health and Care Research Oxford Biomedical Research Centre; the Division of Intramural Research, National Institute of Allergy and Infectious Diseases; the US Agency for International Development; and the Wellcome Trust.
- Open Access
First Phase 1b, single-center, age de-escalation trial of the P. falciparum blood-stage malaria vaccine candidate RH5.1/Matrix-M ™ : a delayed boost regimen induces high levels of functional antibodies in 5-17 month old Tanzanian infants
Background: RH5.1 is a soluble protein vaccine candidate for blood-stage Plasmodium falciparum malaria, previously trialed in healthy UK adults in combination with AS01 B adjuvant. Here, RH5.1 was formulated with Matrix-M™ adjuvant to assess safety and immunogenicity in a malaria-endemic adult and pediatric population for the first time. Methods: We conducted a Phase 1b, single-center, dose-escalation, age de-escalation, first-in-human trial of RH5.1/Matrix-M™ in Bagamoyo, Tanzania. Healthy adults (18-45 years) and infants (5-17 months) were recruited to receive the RH5.1/Matrix-M™ vaccine candidate in a variety of dosing regimens, including monthly dosing (0-1-2 month) or delayed booster dosing (0-1-6 month) using a 10 µg dose of RH5.1, or delayed fractional booster dosing (0-1-6 month) with the first two doses of RH5.1 at 50 µg and the third dose at 10 µg. All RH5.1 protein doses were formulated with 50 µg Matrix-M™ adjuvant. Primary outcomes for vaccine safety included solicited and unsolicited adverse events after each vaccination, along with any serious adverse events (SAEs) during the study period. Secondary outcome measures for immunogenicity included the concentration and avidity of anti-RH5.1 serum IgG antibodies by ELISA and their percentage growth inhibition activity (GIA) in vitro against P. falciparum parasites using purified IgG. All participants receiving at least one dose of vaccine were included in the primary analyses. Findings: Between 25 th January 2021 and 15 th April 2021 a total of 60 adults and infants were enrolled; 57 of these completed the vaccination series, and 55 completed 22 months of follow-up post-third vaccination. Vaccinations were well-tolerated across both age groups. There were five SAEs involving four infant participants during the trial, none of which were deemed related to vaccination. RH5-specific T cell and serum antibody responses were induced by vaccination. The anti-RH5 serum IgG responses were significantly higher in the 5-17 month old infant groups as compared to adults. Serum antibody responses contracted over time post-third vaccination, but a similar hierarchy of responses across the age groups was maintained after 22 months follow-up (674 days post-third vaccination). Vaccine-induced anti-RH5 antibodies showed in vitro GIA with comparable functional quality across all age groups and dosing regimens. The highest anti-RH5 serum IgG responses were observed post-third vaccination in the 5-17 month old infants vaccinated with the 0-1-6 month delayed booster regimen using the 10 µg dose of RH5.1 (median 723 µg/mL; range: 450-1436 µg/mL), resulting in 100 % (11/11 infants) showing >60 % GIA following dilution of total IgG to 2.5 mg/mL (median 88 %; range: 73-97 %). Interpretation: The RH5.1/Matrix-M™ vaccine candidate shows an acceptable safety and reactogenicity profile and highly promising antibody immunogenicity in 5-17 month old infants residing in a malaria-endemic area. The 0-1-6 month delayed booster regimen in 5-17 month old infants induced the highest levels of functional GIA reported to-date following human vaccination, with all infants achieving a level of GIA previously associated with protective outcome against blood-stage P. falciparum challenge in non-human primates. These data support onward efficacy assessment of this vaccine candidate against clinical malaria in young African infants. Funding: The European and Developing Countries Clinical Trials Partnership (EDCTP). Trial Registration: ClinicalTrials.gov: NCT04318002 .
Open AccessFirst Phase 1b, single-center, age de-escalation trial of the P. falciparum blood-stage malaria vaccine candidate RH5.1/Matrix-M ™ : a delayed boost regimen induces high levels of functional antibodies in 5-17 month old Tanzanian infants
Background: RH5.1 is a soluble protein vaccine candidate for blood-stage Plasmodium falciparum malaria, previously trialed in healthy UK adults in combination with AS01 B adjuvant. Here, RH5.1 was formulated with Matrix-M™ adjuvant to assess safety and immunogenicity in a malaria-endemic adult and pediatric population for the first time. Methods: We conducted a Phase 1b, single-center, dose-escalation, age de-escalation, first-in-human trial of RH5.1/Matrix-M™ in Bagamoyo, Tanzania. Healthy adults (18-45 years) and infants (5-17 months) were recruited to receive the RH5.1/Matrix-M™ vaccine candidate in a variety of dosing regimens, including monthly dosing (0-1-2 month) or delayed booster dosing (0-1-6 month) using a 10 µg dose of RH5.1, or delayed fractional booster dosing (0-1-6 month) with the first two doses of RH5.1 at 50 µg and the third dose at 10 µg. All RH5.1 protein doses were formulated with 50 µg Matrix-M™ adjuvant. Primary outcomes for vaccine safety included solicited and unsolicited adverse events after each vaccination, along with any serious adverse events (SAEs) during the study period. Secondary outcome measures for immunogenicity included the concentration and avidity of anti-RH5.1 serum IgG antibodies by ELISA and their percentage growth inhibition activity (GIA) in vitro against P. falciparum parasites using purified IgG. All participants receiving at least one dose of vaccine were included in the primary analyses. Findings: Between 25 th January 2021 and 15 th April 2021 a total of 60 adults and infants were enrolled; 57 of these completed the vaccination series, and 55 completed 22 months of follow-up post-third vaccination. Vaccinations were well-tolerated across both age groups. There were five SAEs involving four infant participants during the trial, none of which were deemed related to vaccination. RH5-specific T cell and serum antibody responses were induced by vaccination. The anti-RH5 serum IgG responses were significantly higher in the 5-17 month old infant groups as compared to adults. Serum antibody responses contracted over time post-third vaccination, but a similar hierarchy of responses across the age groups was maintained after 22 months follow-up (674 days post-third vaccination). Vaccine-induced anti-RH5 antibodies showed in vitro GIA with comparable functional quality across all age groups and dosing regimens. The highest anti-RH5 serum IgG responses were observed post-third vaccination in the 5-17 month old infants vaccinated with the 0-1-6 month delayed booster regimen using the 10 µg dose of RH5.1 (median 723 µg/mL; range: 450-1436 µg/mL), resulting in 100 % (11/11 infants) showing >60 % GIA following dilution of total IgG to 2.5 mg/mL (median 88 %; range: 73-97 %). Interpretation: The RH5.1/Matrix-M™ vaccine candidate shows an acceptable safety and reactogenicity profile and highly promising antibody immunogenicity in 5-17 month old infants residing in a malaria-endemic area. The 0-1-6 month delayed booster regimen in 5-17 month old infants induced the highest levels of functional GIA reported to-date following human vaccination, with all infants achieving a level of GIA previously associated with protective outcome against blood-stage P. falciparum challenge in non-human primates. These data support onward efficacy assessment of this vaccine candidate against clinical malaria in young African infants. Funding: The European and Developing Countries Clinical Trials Partnership (EDCTP). Trial Registration: ClinicalTrials.gov: NCT04318002 .
- Open Access
- 12 July 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (704) , eadf1782
Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection
There are no licensed vaccines against Plasmodium vivax . We conducted two phase 1/2a clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII). Recombinant viral vaccines using chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) vectors as well as a protein and adjuvant formulation (PvDBPII/Matrix-M) were tested in both a standard and a delayed dosing regimen. Volunteers underwent controlled human malaria infection (CHMI) after their last vaccination, alongside unvaccinated controls. Efficacy was assessed by comparisons of parasite multiplication rates in the blood. PvDBPII/Matrix-M, given in a delayed dosing regimen, elicited the highest antibody responses and reduced the mean parasite multiplication rate after CHMI by 51% ( n = 6) compared with unvaccinated controls ( n = 13), whereas no other vaccine or regimen affected parasite growth. Both viral-vectored and protein vaccines were well tolerated and elicited expected, short-lived adverse events. Together, these results support further clinical evaluation of the PvDBPII/Matrix-M P. vivax vaccine.
- 12 July 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (704) , eadf1782
Open AccessVaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection
There are no licensed vaccines against Plasmodium vivax . We conducted two phase 1/2a clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII). Recombinant viral vaccines using chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) vectors as well as a protein and adjuvant formulation (PvDBPII/Matrix-M) were tested in both a standard and a delayed dosing regimen. Volunteers underwent controlled human malaria infection (CHMI) after their last vaccination, alongside unvaccinated controls. Efficacy was assessed by comparisons of parasite multiplication rates in the blood. PvDBPII/Matrix-M, given in a delayed dosing regimen, elicited the highest antibody responses and reduced the mean parasite multiplication rate after CHMI by 51% ( n = 6) compared with unvaccinated controls ( n = 13), whereas no other vaccine or regimen affected parasite growth. Both viral-vectored and protein vaccines were well tolerated and elicited expected, short-lived adverse events. Together, these results support further clinical evaluation of the PvDBPII/Matrix-M P. vivax vaccine.
- Open Access
- 31 March 2023
- Published by Elsevier in Clinical Infection in Practice
- Vol. 19, 100223
Prescribing in a pandemic: Electronic prescribing aids to improve non-specialist adherence to COVID-19 guidelines
- 31 March 2023
- Published by Elsevier in Clinical Infection in Practice
- Vol. 19, 100223
Open AccessPrescribing in a pandemic: Electronic prescribing aids to improve non-specialist adherence to COVID-19 guidelines